

Hexima Limited

HXP124: a game-changing treatment for fungal infections

Public Offer and ASX Listing
October 2020

Hexima Limited



Summary information

This presentation has been prepared by Hexima Ltd and its subsidiaries (collectively “Hexima”). The information in this presentation is of general background in summary form which is current as at Thursday 15 October 2020 and does not purport to be complete. It does not contain all information relevant or necessary for an investment decision or that would be required to be included in a prospectus under the Corporations Act 2001 (Cth) (**Corporations Act**). The information in this presentation is subject to change without notice. No representation or warranty, express or implied, is made by Hexima or any of its advisers as to the accuracy, adequacy or reliability of any information contained in this presentation.

Not an offer

This presentation is not a prospectus or any other offering document under Australian law or any other law (and will not be lodged with ASIC). This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this presentation outside Australia may be restricted by law. Any recipient of this presentation who is outside Australia must seek advice on and observe any such restrictions. This presentation may not be reproduced or published, in whole or in part, for any purpose without the prior written permission of Hexima. An investment in securities is subject to known and unknown risks, some of which are beyond the control of Hexima, including possible loss of income and principal invested. Hexima does not guarantee any particular rate of return or the performance of Hexima, nor does it guarantee any particular tax treatment. Investors should have regard to potential risks outlined in this presentation when making their investment decision.

Not financial or product advice

This presentation is for information purposes only and is not a prospectus, product disclosure statement or other offer document under Australian law or the law of any other jurisdiction. This document is not a financial product or investment advice, or a recommendation to acquire securities in Hexima, nor is it legal or tax advice. It has been prepared without taking into account the objectives, financial situation or needs of individuals. You are solely responsible for seeking independent and professional advice in relation to the information contained in this presentation and any action taken on the basis of that information. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial and tax situation and needs and seek legal and taxation advice appropriate to their jurisdiction. No reliance may be placed for any purpose whatsoever on the information included in this presentation or on its accuracy or completeness.

Financial data

All dollar values are in Australian dollars (A\$) unless stated otherwise.

Performance

Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance. The presentation includes forward-looking statements regarding future events and the future financial performance of Hexima. Forward looking words such as “expect”, “should”, “could”, “may”, “predict”, “plan”, “will”, “believe”, “forecast”, “estimate”, “target” or other similar expressions are intended to identify forward-looking statements. Any forward looking statements included in this document involve subjective judgment and analysis and are subject to significant uncertainties, risks and contingencies, many of which are outside the control of, and are unknown to, Hexima and its officers, employees, agents or associates. In particular, factors such as outcomes of clinical trials and regulatory decisions and processes may affect the future operating and financial performance of Hexima. This may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. The information also assumes the success of Hexima’s business strategies. The success of the strategies is subject to uncertainties and contingencies beyond control, and no assurance can be given that the anticipated benefits from the strategies will be realised in the periods for which forecasts have been prepared or otherwise. Given these uncertainties, you are cautioned to not place undue reliance on any such forward looking statements. Hexima is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Disclaimer

Except as required by law, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness, reliability or correctness of the Information, opinions and conclusions, or as to the reasonableness of any assumption contained in this presentation. By receiving this presentation and to the extent permitted by law, you release Hexima and its officers, employees, agents and associates from any liability (including, without limitation, in respect of direct, indirect or consequential loss or damage or loss or damage arising by negligence) arising as a result of the reliance by you or any other person on anything contained in or omitted from this presentation. To the maximum extent permitted by law, Hexima and its respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents exclude and disclaim all liability, including without limitation for negligence or for any expenses, losses, damages or costs incurred by you as a result of the information in the presentation being inaccurate or incomplete in any way for any reason, whether by negligence or otherwise. To the maximum extent permitted by law, Hexima and its advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this presentation.



Overview

- **Hexima is a Melbourne-based biotechnology company developing HXP124, a potential new topical treatment for onychomycosis**
- **Onychomycosis (fungal nail infection) represents a large and growing market with substantial unmet need**
 - Estimated to affect up to 14% of the population, **globally the market for treatment of onychomycosis has been estimated at US\$3.7 bn.**
 - Well developed market in US and Japan with sales of the leading topical product, efinaconazole, exceeding US\$320m in 2019
 - Current topical products suffer from poor efficacy rates and long treatment durations, oral treatments are more effective but can have toxic side effects
- **HXP124 is a potentially game-changing treatment**
 - Demonstrated in a phase I/IIa clinical trial to have a favourable safety profile and deliver effective and rapid anti-fungal treatment
 - **High efficacy** via a topical application with novel mode of action
 - **Fast acting treatment** reducing treatment duration
 - **No toxic side effects**
 - Currently in an Australian phase IIb clinical trial for onychomycosis
- **Hexima's highly experienced management and scientific team and commercial board of directors have a strong track record in bringing novel biotech solutions to market**
 - >\$25 million invested in research and development of HXP124 to date
- **HXP124 represents a compelling commercial opportunity in the US and globally**
 - Hexima aims to position HXP124 to be the **treatment of choice for an unsatisfied, consumer-driven market**
- **Hexima is currently seeking to raise \$3.0 million in conjunction with a re-listing on the ASX in Q4 2020**
 - Existing shareholders will be provided with a sale facility, and with a priority under the public offer



Investment highlights

- 1 The market for onychomycosis treatments is large and growing**
The global market for all forms of onychomycosis treatments in 2018 was estimated at US\$3.7 billion, the disease impacts >500 million people
- 2 There is a well defined and unmet medical need for a safe, effective and rapidly acting topical product**
Clinicians and patients are frustrated by the long treatment times and modest efficacy rates of current topical treatments
- 3 HXP124 poised to become the best-in-class onychomycosis treatment**
HXP124 has shown 2-fold better Mycological Cure* at 12 weeks than current topical treatments, following 6-weeks treatment with a better safety profile
- 4 HXP124 promise of excellent efficacy without toxic side effects**
HXP124 promises to deliver cure rates approaching oral drugs but without their attendant toxic side effects
- 5 The market opportunity in the US for HXP124 has been independently tested and verified**
Specialist healthcare market research firm ClearView Healthcare Partners assessed the market opportunity for HXP124 in the U.S.
- 6 HXP124 represents a compelling commercial opportunity in the US and globally**
HXP124 has the potential to drive significant worldwide sales
- 7 Hexima has a strong, long life, global portfolio of intellectual property**
Patents granted in the US, Japan and Europe; patents pending in other key jurisdictions including China
- 8 Hexima is managed by a highly experienced senior leadership team with substantial equity ownership**
Hexima's senior leadership team has significant clinical trial and product development experience, and currently owns 23%** of the company

Note: *Mycological Cure = no fungus in samples collected from underneath the nail as assessed by stain (microscopy) and culture (growth); ** On a fully diluted basis



The market for onychomycosis treatments is large and growing

Key Insights



Onychomycosis of the toenail is estimated to affect up to 14% of the population, growth in the market is primarily driven by an ageing population



Risk factors include increasing age, athlete's foot, diabetes, and immunodeficiency.




Patients experience pain and difficulty wearing shoes. Quality of life is affected by nail dystrophy and unacceptable cosmetic appearance



Only ~35% of patients seek treatment. Large potential for growth with an effective product

Topical products are preferred over oral treatments, but existing products fail to meet fundamental patient needs



There has been a sustained shift in the market to favor prescription of topical agents over oral agents, demonstrating growing **demand for safe and effective topical therapies**

HXP124 has the potential to become a game-changing, best-in-class treatment given its efficacy, safety and speed of action





	 Terbinafine	 Tavaborole	 Efinaconazole	 Ciclopirox	 HXP124
Product type	Oral	Topical	Topical	Topical	Topical
Fast acting	✓	✗	✗	✗	✓
Efficacious	✓	✗	✗	✗	✓
No systemic toxicity	✗	✓	✓	✓	✓
No local side effects	N/A	✗	✗	✓	✓

HXP124 has the potential to become the best available treatment on the market: better response than current topical treatments (approaching that of oral drugs), but with a substantially shorter treatment time and a much improved safety profile



Plant defensins

- The unique physical properties of defensins lend HXP124 to the task of safely penetrating the nail and clearing infection




NMR structure of HXP124

HXP124 kills fungi more readily than other treatments for nail infections



- HXP124 kills fungal cells within 30 minutes via a novel mode of action
- Ineffective killing by drugs currently on the market means the fungus often regrows when treatment is stopped
- HXP124 is specific for fungal cells and does not impact the viability of human cells






Fluorescence Associated Cell Sorting (FACS) of Propidium Iodide stained cells was used to identify living and dead *Candida albicans* cells after 30 min treatment with antifungal agents

Note: Internal Hexima Study

HXP124 penetrates nails faster and more efficiently than current marketed products



- Topical treatments for fungal nail disease must penetrate human nails to reach the nail bed, the main site of infection
 - Nail penetration of existing topical drugs is a major barrier to treatment efficacy



Note: 1 Internal Hexima Study


2 Kaken Pharma and Dow Pharma, Sugiura et al., 2014;

3 UCSF Medical Center, Hui et al., 2006



Successful phase I/IIa clinical trial

- Randomised, double blind cohort study
- Patients treated nails daily with HXP124 (or vehicle) for 6 weeks with follow-up at 12 weeks
 - Total of 48 patients – 36 treated with HXP124, 12 treated with vehicle
 - Unblinded follow-up at 52 weeks only for Cohort 4





HXP124 is safe when applied to nails daily for 42 days

The primary endpoint for the phase I/IIa study was safety and tolerability



HXP124 is **safe and well tolerated**. No drug-related adverse events.



HXP124 **did not cause local irritation** and did not enter the bloodstream.
There was **no systemic toxicity**.

During a phase I/IIa trial HXP124 delivered effective and rapid anti-fungal treatment for patients



Key Insights from Phase I/IIa clinical trial




Mycological cure (culture and stain negative) was achieved in **52% of HXP124-treated nails** within 12 weeks (vehicle 24%)



HXP124 produced a high Mycological Cure* rate at 12 weeks, ~2-fold higher than current treatments, after only 6 weeks of treatment


Mycological Cure at 12 weeks



Note: *Mycological Cure = no fungus in samples collected from underneath the nail as assessed by stain (microscopy) and culture (growth).




During a phase I/IIa trial HXP124 substantially improved onychomycosis symptoms



HXP124 cleared the affected nail area more effectively than formulation not containing HXP124



Clinical efficacy (defined as <10% of the nail area affected) was **achieved in 20% of HXP124-treated nails** within just 12 weeks (vehicle 6%)





During a phase I/IIa trial HXP124 delivered significant improvement in nail appearance within 12 weeks

Prior to treatment



12 weeks after treatment commenced

Baseline



Week 12



Baseline



Week 12



Baseline



Week 12






**Given HXP124's safety & efficacy profile, Hexima believes
it has the potential to deliver best-in-class cure rates
without the toxic side effects of oral alternatives**



Proposed Australian Phase IIb clinical trials

- Multi-center, randomised, double blind, vehicle-controlled study
- Three active arms versus vehicle (132 subjects)
 - Comparing three dosing strategies
- Safety & efficacy assessed at 13, 24, 36 and 40 weeks
 - Assessments align with those used for Jublia[®] during phase II study
- Inclusion/exclusion criteria align with those used for Jublia[®] phase III study

36 week treatment – 40 week follow-up





HXP124 can be produced rapidly and economically



HXP124 is produced in a non-proprietary yeast expression system with a **highly competitive cost of goods**



HXP124 has been **manufactured under Good Manufacturing Practice (GMP)** conditions. Commercial-scale contract manufacturer engaged.



Drug product **retains activity when stored at room temperature for 24 months**



Hexima has developed strong protection for its world-leading Intellectual Property, creating a strong foundation from which to launch HXP124



World-leading IP portfolio



Hexima has built a **world leading competency in plant defensins** and a broad IP portfolio

Globally recognised scientists

Extensive IP protection in key international markets



Patents granted in the US, Japan and Europe for HXP124 to treat fungal nail infections, patents pending in several other major jurisdictions, including China

- 15 years patent life remaining, plus any available patent term extensions

30 patents for HXP124 in 2 patent families

Clearly defined growth strategy



HXP124 is a biologic, eligible for 12 years marketing exclusivity in the US

Strategy is to **develop independently in US and EU markets**



- Considering a licensing strategy in non-US and non-EU countries

\$>25m invested in research and development of HXP124

Hexima is run by an experienced senior executive team who are invested in the success of the company



Board of Directors and Senior Executive Team



Prof. Jonathan West
Non-Executive Chair

- Former Assoc. Prof. at Harvard Business School
- Founding Director of Australian Innovation Research Centre
- Advisor to major corporates including DuPont, Roche, Novartis and Syngenta.

3.3%
ownership

Mr Justin Yap
Non-Executive Director

- Non-Executive Director of CathRx Limited
- Non-executive Director Wilhelm Integrated Solutions
- Formerly at Mosaic Risk Management (Wilson HTM)

10.5%
ownership

Scott Robertson
Non-Executive Director

- MBA (Haas School of Business)
- Former Business Development Director at DuPont Pioneer
- Former investment professional at MPM Capital, a life science-dedicated venture capital fund
- Current CFO at DiCE Molecules

0.2%
ownership

Michael Aldridge
Executive Director
Chief Executive Officer

- CEO Peplin Inc., sold to Leo Pharma in 2009 for \$300M
- SVP Corporate Strategy Questcor, sold to Mallinckrodt in 2014 for US\$5.6b
- SVP Corporate & Strategic Development Codexis, US\$357M partnership with Nestle in PKU in 2017

1.8%
ownership

Dr. Nicole van der Weerden
Executive Director
Chief Operating Officer

- PhD (La Trobe University)
- MBA (Melbourne Business School)
- Inventor on all of Hexima's key patents
- Led discovery and development program for HXP124
- CEO of Hexima 2015 -2020

1.3%
ownership

Prof. Marilyn Anderson AO
Executive Director
Chief Science Officer

- Founding scientist of Hexima
- Fellow of the Australian Academy of Science and Australian Academy of Technological Sciences
- Executive Director of Hexima since 2010

1.7%
ownership

Dr Peter Welburn
Chief Development Officer

- CSO and VP Research & Development Peplin Inc., NDA for PEP005 Gel approved 2012
- General Manager Leo Pharma (Australia)
- Consultant to Codexis on CDX6114 for PKU

0.4%
ownership

Hexima considers that HXP124 presents a highly compelling commercial opportunity



Strong Clinical Profile

Market demand for greater efficacy with shorter treatment durations than current topical agents, **indicates potential for HXP124 to become their preferred topical product**



Ability to Differentiate vs. Standard of Care

The limited efficacy and long treatment durations required by current topical drugs creates the **opportunity to differentiate HXP124 from current drugs and drive uptake**



Potential for Antifungal Market Growth

Historic responsiveness of the market to the Jublia® product launch and promotional campaigns highlights **potential for growth in overall prescription market with HXP124**

Implications


HXP124 has a meaningful and achievable commercial opportunity

*Based on the expected profile and phase I/IIA results, HXP124 has the potential to **outperform existing topical antifungal therapies***

The product development roadmap of HXP124 involves several clearly defined activities over the mid-term



Detailed product development timeline



Note: * IND = Investigational New Drug Application, required to conduct clinical trials in the US; ** FDA = US Food and Drug Administration;

Hexima is committed to the execution of a sound strategic plan, whilst preserving options to maximise shareholder returns



High-level strategic roadmap

Raise capital for, conduct, and complete Phase IIb clinical trials in Australia

Secure collaborative partnership in Japan

Secure funding for, undertake, and complete Phase III clinical trials in the US

Maintain dialogue with potential partners (or acquirors) for HXP124 in US & EU

Flexibility to pursue other strategic alternatives

Strategic alternatives designed to retain flexibility and maximise shareholder returns / value

Trade sale of HXP124 (or Hexima) to an international pharmaceutical company at inflection points (including completion of Australian Phase IIb trials; or completion of US trials)

Pursue a licencing arrangement of HXP124 for onychomycosis in Japan (process underway), or in the US, EU or Globally



Public Offer Indicative Capital Structure

- Hexima is raising A\$3.0 million via a Public Offer at \$0.20 per share and re-listing on the ASX
- A priority will be given to existing shareholders under the Public Offer
- A share sale facility will also be included in the Offer for existing shareholders at the same price as the Public Offer for up to 22.5 million shares

Indicative Capital Structure	Shares	% Ownership (Undiluted)	Gross Amount Raised	Implied Market Cap at Public Offer Price
Existing Shareholders	115.9m	88.5%	-	\$23.2m
Public Offer Capital Raising	15.0m	11.5%	\$3.0m	\$3.0m
Total Post Offer	130.9m	100.0%	\$3.0m	\$26.2m

- Hexima has a Long Term Incentive Plan (LTIP) under which the Board may issue share, options, performance rights or share appreciation rights to employees, directors and consultants
- The total number of shares to be issued under the LTIP is limited to 10% of the total number of issued Shares at the time of granting the Awards.



Use of Funds & Indicative Timetable

USE OF FUNDS AND EXISTING CASH	A\$
Existing Cash Balances as at 30 September 2020*	\$5.5m
R&D tax incentive refund (expected November 2020)	\$1.9m
Gross Proceeds of the Offer	\$3.0m
Total Cash on Completion of the Offer	\$10.4m
Phase IIb clinical trial	\$3.4m
Scale-up of HXP124 manufacture	\$1.2m
Formulation, stability & chemistry, manufacture & controls	\$0.7m
Toxicology studies	\$2.0m
Market research	\$0.1m
Costs of the Offer	\$0.7m
Working capital	\$2.4m
TOTAL	\$10.4m

INDICATIVE TIMETABLE	2020
Prospectus Lodgement	Mid October
Offer opens	Late October
Share Sale Facility closes	Early November
Public Offer closes	Mid November
Shares commence trading on ASX	Late November

Indicative timetable is subject to change

HXP124 is well-positioned to become the market-leading treatment for onychomycosis globally



Hexima has extensive understanding of the HXP124 molecule, and is the world leader in this class of proteins



HXP124's high (>50%) mycological cure rate after just 6 weeks of daily application.
The Australian phase IIb trial will assess 12-30 week courses of treatment.



HXP124 has the potential to address the well-defined and unmet medical need of millions of patients suffering from the disfiguring and often painful disease, and who are inadequately served by existing treatments. It is also highly cost-effective to manufacture



Medical practitioners surveyed have indicated a product with HXP124's characteristics (efficacy, treatment duration, safety, etc.) would likely be prescribed as a priority ahead of competing products



Historically the failure in onychomycosis product development and commercialisation has occurred because of:

- potential toxicity through ingesting a tablet with harmful side effects;
- limited efficacy;
- inability to kill fungus; and
- inability of topical products to penetrate the nail

Based on documented studies, HXP124 does not suffer any of the above limitations



Hexima has strong patent protections in all key markets, and a clear roadmap for successfully developing HXP124

Through HXP124, Hexima is positioned to deliver meaningful solutions to patients and significant value to its investors



Contacts

- Michael Aldridge, Chief Executive Officer
m.aldridge@hexima.com.au
+1 650 452 4684
- Dr Nicole van der Weerden, Chief Operating Officer
n.vanderweerden@hexima.com.au
+61 407 039 983

Further information is available (including audited annual accounts) at the Company's website:
www.hexima.com.au